Q3 EPS Estimates for AnaptysBio Reduced by Leerink Partnrs

AnaptysBio, Inc. (NASDAQ:ANAB) – Leerink Partnrs decreased their Q3 2025 earnings per share estimates for AnaptysBio in a report released on Tuesday, September 30th. Leerink Partnrs analyst D. Risinger now expects that the biotechnology company will post earnings of ($0.85) per share for the quarter, down from their prior estimate of ($0.84). The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share. Leerink Partnrs also issued estimates for AnaptysBio’s Q4 2025 earnings at $1.04 EPS, FY2025 earnings at ($1.69) EPS, FY2026 earnings at ($2.98) EPS, FY2027 earnings at ($3.01) EPS, FY2028 earnings at ($1.87) EPS and FY2029 earnings at ($0.82) EPS.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.50) by $0.16. The company had revenue of $22.26 million for the quarter, compared to analysts’ expectations of $11.55 million. AnaptysBio had a negative net margin of 107.66% and a negative return on equity of 366.98%.

A number of other equities research analysts also recently issued reports on the stock. Wedbush reaffirmed an “outperform” rating and set a $45.00 price target on shares of AnaptysBio in a research note on Tuesday, September 30th. Weiss Ratings restated a “sell (d-)” rating on shares of AnaptysBio in a research report on Saturday, September 27th. HC Wainwright lifted their price target on AnaptysBio from $38.00 to $59.00 and gave the stock a “buy” rating in a research report on Tuesday, September 30th. JPMorgan Chase & Co. boosted their price objective on AnaptysBio from $42.00 to $80.00 and gave the stock an “overweight” rating in a research note on Thursday, July 24th. Finally, UBS Group reaffirmed a “neutral” rating and issued a $20.00 price objective (up from $18.00) on shares of AnaptysBio in a research note on Tuesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.75.

AnaptysBio Stock Performance

Shares of NASDAQ ANAB opened at $30.94 on Friday. The company has a market cap of $866.32 million, a PE ratio of -6.91 and a beta of -0.18. AnaptysBio has a 52-week low of $12.21 and a 52-week high of $36.54. The firm’s 50 day moving average price is $22.42 and its 200-day moving average price is $21.88.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ANAB. California State Teachers Retirement System grew its stake in AnaptysBio by 10.3% in the fourth quarter. California State Teachers Retirement System now owns 14,590 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 1,359 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of AnaptysBio by 0.8% in the 4th quarter. Wellington Management Group LLP now owns 66,467 shares of the biotechnology company’s stock valued at $880,000 after buying an additional 528 shares in the last quarter. GAMMA Investing LLC purchased a new position in shares of AnaptysBio in the 1st quarter worth approximately $113,000. Rhumbline Advisers raised its stake in shares of AnaptysBio by 2.7% during the 1st quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company’s stock worth $574,000 after acquiring an additional 826 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its position in AnaptysBio by 9,778.9% during the first quarter. Farther Finance Advisors LLC now owns 1,877 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 1,858 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.